Lumanity
Therapeutic Science and Strategy
In this podcast series, Joel Sandler, Principal, BioConsulting, Cancer Cell Therapy Lead, sits down with various guests to talk about important topics that impact the pharmaceutical, biotech, and medical device industries.
Обов'язково відвідайте сайт подкасту та підтримайте його автора: sites.libsyn.com
Де слухати?
Подкасти в застосунку Replaio Radio Уже незабаромПодкасти незабаром з'являться в застосунку. Встановіть уже зараз і першими побачте зовсім новий погляд на подкасти
Епізоди
Changing the Narrative: The Story of an Ultra-rare Cancer Patient 31.05.2022 25:11
In this podcast series, Joel Sandler, Principal, Cancer Cell Therapy Lead, sits down to talk about relevant and important content. In this third episode, Joel sits down with Michael 'Mitch' Petrick, anaplastic thyroid cancer patient, to explore: Mitch's background and his rare form of thyroid cancer His journey from initial diagnosis (which he made!) through to referral and treatment Some thoughts...
CAR-T in Solid Tumors: A Cancer Progress Sneak Peek 25.04.2022 22:47
In this podcast series, Joel Sandler, Principal, Cancer Cell Therapy Lead, sits down to talk about relevant and important content. In this second episode, Joel sits down with Shivani Srivastava, PhD, Assistant Professor Human Biology Division, Fred Hutchinson Cancer Research Center , to explore: Key challenges to addressing solid tumors with cell therapy Recent developments (technology, scientifi...
Not So Rare: Win-wins in Ultra-orphan Diseases 25.02.2022 18:40
In this podcast series, Joel Sandler, Principal, Cancer Cell Therapy Lead, sits down to talk about relevant and important content. In this first episode, Joel sits down with Michael Parisi, CEO of Guidemark, and Michael Rice, Vice President, Head of Advanced Therapeutics, to explore: How uncovering NSCLC and SMA genetics led to record-speed options for patients with rare subtypes How the patient a...
Схожі подкасти
Replaio не є видавцем подкастів; назви шоу, обкладинки та аудіо належать їхнім авторам і поширюються через публічні RSS-канали